Skip to main content

Advertisement

SpringerLink
Log in

Managing HIV and Hodgkin Lymphoma in the Twenty-first century

  • Lymphomas (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Hodgkin lymphoma (HL) is more frequent in patients with Human Immunodeficiency Virus (HIV) infection than in immunocompetent patients. The relationship between the immune system and HL is complex. Whilst the incidence of HL in HIV patients has most likely increased since the introduction of combined anti-retroviral therapy (cART), there is no doubt that the outcomes for patients with HIV and HL (HIV-HL) have improved since its introduction. Improved CD4 counts and risk-adapted treatment schedules have resulted in outcomes for patients with HIV-HL that are comparable to those in HIV-negative patients with HL. Thus, HIV-HL should be treated in the same way as HL in immunocompetent patients, including the use of salvage chemotherapy and autologous transplant in the relapsed setting in HIV-HL. Along the same lines, patients with HIV-HL should not be excluded from trials based on their immune status alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Eichenauer D, Engert A. Lymphomas. Essentials For Clinicians. First ed. Switzerland: ESMO Press; 2012:67-72.

  2. Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematol Am Soc Hematol Educ Program. 2013;2013:382–8.

    Article  Google Scholar 

  3. Seaberg EC, Wiley D, Martínez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer. 2010;116(23):5507–16.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113(23):5737–42.

    Article  PubMed  CAS  Google Scholar 

  5. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187–94.

    Article  PubMed  CAS  Google Scholar 

  7. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611–22.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Bohlius J. HIV-related Hodgkin Lymphoma in the era of HAART: Incidence and survival in a European multi-cohort study: Preliminary results. HIV Med. 2009;10:37.

    Article  Google Scholar 

  10. Bower M, Palfreeman A, Alfa-Wali M, et al. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15 Suppl 2:1–92.

    Google Scholar 

  11. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506–14.

    Article  PubMed  CAS  Google Scholar 

  12. Spina M, Re A, Vaccher E, Gabarre J, Tirelli U. High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. Ann Oncol. 2003;14(4):655–6.

    Article  PubMed  CAS  Google Scholar 

  13. Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117–23. This is the first prospective risk-adapted therapy in HIV-associated Hodgkin Lymphoma.

    Article  PubMed  Google Scholar 

  14. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265–73.

    Article  PubMed  Google Scholar 

  15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  16. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38(10):1575–83.

    PubMed  Google Scholar 

  17. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  PubMed  CAS  Google Scholar 

  18. Radford J, Barrington S, Counsell N, al. e. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. Am Soc Haematol; 2012.

  19. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12.

    Article  PubMed  CAS  Google Scholar 

  20. Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol. 1999;10(2):189–95.

    Article  PubMed  CAS  Google Scholar 

  21. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24(5):444–50.

    Article  PubMed  CAS  Google Scholar 

  22. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100(6):1984–8.

    Article  PubMed  CAS  Google Scholar 

  23. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica. 2007;92(2):191–8.

    Article  PubMed  CAS  Google Scholar 

  24. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111–6.

    Article  PubMed  Google Scholar 

  25. Kaplan LD. Management of HIV-associated Hodgkin lymphoma: how far we have come. J Clin Oncol. 2012;30(33):4056–8.

    Article  PubMed  CAS  Google Scholar 

  26. Jacobson CA, Abramson JS. HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol. 2012;2012:507257.

    PubMed  PubMed Central  Google Scholar 

  27. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4.

    Article  PubMed  CAS  Google Scholar 

  28. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  PubMed  CAS  Google Scholar 

  29. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89(9):1100–8.

    PubMed  Google Scholar 

  30. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105(2):874–8.

    Article  PubMed  CAS  Google Scholar 

  31. Serrano D, Carrión R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33(4):487–94.

    Article  PubMed  CAS  Google Scholar 

  32. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14(1):59–66.

    Article  PubMed  CAS  Google Scholar 

  33. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21(23):4423–7.

    Article  PubMed  CAS  Google Scholar 

  34. Díez-Martín JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113(23):6011–4. This study demonstrates the success of autologous transplantation regardless of immune status.

    Article  PubMed  Google Scholar 

  35. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13.

    Article  PubMed  CAS  Google Scholar 

  36. Re A, Cattaneo C, Skert C, et al. Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica. 2013;98(11):1762–8.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Gupta V, Tomblyn M, Pederson T, et al. Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with malignant and non-malignant disorders: a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Vol 8: Blood; 2006:5353.

  38. Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11(4):223–38.

    Article  PubMed  CAS  Google Scholar 

  39. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. This is the first randomised study of a new drug in first line, in Hodgkin Lymphoma. It is not on HIV positive patients but represents an important first step, highlighting the necessity of recruiting HIV positive patients for inclusion in such trials.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. James Aries and Dr. Silvia Montoto each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Haemato-oncology St Bartholomew’s Hospital, Barts Health NHS Trust, 45 Little Britain, West Smithfield, EC1A 7BE, UK

    James Aries & Silvia Montoto

Authors
  1. James Aries
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Montoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Montoto.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aries, J., Montoto, S. Managing HIV and Hodgkin Lymphoma in the Twenty-first century. Curr Hematol Malig Rep 9, 227–232 (2014). https://doi.org/10.1007/s11899-014-0215-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-014-0215-4

Keywords

Search

Navigation